Talecris Biotherapeutics Holding Corp., a Research Triangle Park, N.C.-based developer of plasma-derived protein therapies, last month filed a pair of amendments to its original IPO filing. Neither amendment disclosed the number of shares to be offered or a price range, but did indicate that the company still plans to go public.
Talecris had originally filed for a $1 billion IPO in 2007, but later agreed to be acquired by Australia’s CSL Ltd. for $3.1 billion. That deal was scuttled by anti-trust regulators. Talecris is controlled by Cerberus Management and Ampersand Ventures. www.talecris.com